Renegade Bio

Fast, accessible, and secure triage for COVID-19

Renegade Bio operates in diagnostics based in Berkeley, California, US, founded in 2020.

Profile

Renegade.bio invented an improvement on the CDC testing method for COVID-19, turning four reactions into a single-step that doesn’t require RNA extraction. By dramatically improving turnaround time and capacity of testing machines, the RenegadeXP™method is 70% cheaper and takes half the time of a standard CDC test, with a net >4x increase in throughput. Renegade.bio has submitted an emergency use authorization application to the FDA for its RenegadeXP™ test. In mid-April, Renegade.bio partnered with a well-known genetic research institute in New York City to operate a CLIA-certified laboratory to test government workers and medical personnel. The New York City laboratory is capable of running 1,300 tests every day, and will grow to serve a capacity of at least 20,000 tests per week by the end of June. Renegade.Bio – Viral Testing that’s cheaper, faster, more than 4x Throughput

Renegade Bio is positioned in diagnostics, a segment that rewards a clear, focused offering.

The company is recorded as being based in Berkeley, California, US.

Its current recorded stage is SOSV portfolio company.

Its team size is recorded as 11-50 employees.

Website: renegade.bio